Clinical observation of intravitreal conbercept combined laser photocoagulation for treatment of diabetic macular edema
Objective To observe the efficacy of intravitreal conbercept combined laser photocoagulation for treatment of diabetic macular edema(DME).Methods DME patients treated in outpatient of Zhengzhou Yangcheng Hospital de-partment from March 2021 to March 2022 were selected,24 eyes were randomly selected for the vitreous cavity injection combined with photocoagulation group and the other 24 eyes were the photocoagulation therapy group(pure group).There was no significant difference between the best-corrected visual acuity(BCVA)and central macular retinal thick-ness(CMT).Patients in the combination group were treated with intravitreal injection,and the standard photocoagula-tion in the macular area one week later.Patients in the pure group were treated with only the macular area,comparing the changes of best corrected visual acuity(BCVA)and central macular retinal thickness(CMT)before and after treat-ment.Results No significant differences were found between age,baseline CMT value,baseline best corrected visual acuity,P>0.05.In the combination group,the vision level of 1 week,1 month and 3 months after therapy were higher than that of the pure group,P<0.05.There was no significant difference in visual acuity between the two groups,P>0.05.The CMT of the combined group was lower than that of the simple group P<0.05.There was no significant difference in CMT between the two groups P>0.05.The incidence of increased IOP after intravitreal injection of combined group was 4.2%.No complication was observed in two groups during the follow-up duration.Conclusion Compared with laser treatment alone,the recent effect of Compacercept combined with macular grille-like laser photocoagulation in DME pa-tients is significant,which can effectively improve macular edema,improve central vision,with mild adverse reactions,high safety and high patient satisfaction.However,its long-term efficacy and safety need further study.